9
Sep
2016

Reflections from Yellowstone, EpiPen’s Foul Aftermath, and Saunders Steps Up

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Vertex Antes for Alpine, Regeneron Faces DOJ Scrutiny, & the Illumina Shakeup
A ProfoundBio Windfall, Amylyx Yanks Failed ALS Drug, & Verve’s Rough Patch
Boundless’ IPO, Merck’s Acceleron Win, & Moderna’s $750M Flu Vaccine Boost
Megarounds Return, AZ Buys a Radiopharma Player, & Lonza’s California Dream